SA522441725B1 - مركب فثالازينون وطريقة تحضيره واستخدامه الطبي - Google Patents
مركب فثالازينون وطريقة تحضيره واستخدامه الطبيInfo
- Publication number
- SA522441725B1 SA522441725B1 SA522441725A SA522441725A SA522441725B1 SA 522441725 B1 SA522441725 B1 SA 522441725B1 SA 522441725 A SA522441725 A SA 522441725A SA 522441725 A SA522441725 A SA 522441725A SA 522441725 B1 SA522441725 B1 SA 522441725B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- preparation
- compound
- medical use
- phthalazinone
- phthalazinone compound
- Prior art date
Links
- -1 Phthalazinone compound Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010536221 | 2020-06-12 | ||
| CN202011147078 | 2020-10-23 | ||
| CN202011261665 | 2020-11-12 | ||
| CN202110485680 | 2021-04-30 | ||
| CN202110614030 | 2021-06-02 | ||
| PCT/CN2021/099654 WO2021249534A1 (zh) | 2020-06-12 | 2021-06-11 | 酞嗪酮类化合物及其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522441725B1 true SA522441725B1 (ar) | 2024-08-11 |
Family
ID=78846889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522441725A SA522441725B1 (ar) | 2020-06-12 | 2022-12-12 | مركب فثالازينون وطريقة تحضيره واستخدامه الطبي |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20230131252A1 (https=) |
| EP (1) | EP4166550A4 (https=) |
| JP (2) | JP7797421B2 (https=) |
| KR (1) | KR20230024328A (https=) |
| CN (2) | CN113801098B (https=) |
| AU (1) | AU2021286738A1 (https=) |
| BR (1) | BR112022025057A2 (https=) |
| CA (1) | CA3186981A1 (https=) |
| CL (1) | CL2022003472A1 (https=) |
| CO (1) | CO2022017802A2 (https=) |
| CR (1) | CR20230007A (https=) |
| IL (1) | IL298962A (https=) |
| MX (1) | MX2022015562A (https=) |
| PE (1) | PE20230610A1 (https=) |
| PH (1) | PH12023550018A1 (https=) |
| SA (1) | SA522441725B1 (https=) |
| TW (1) | TWI781651B (https=) |
| WO (1) | WO2021249534A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN114829342A (zh) | 2019-12-23 | 2022-07-29 | 上海济煜医药科技有限公司 | 一种蛋白降解剂化合物的制备方法和应用 |
| JP2023520916A (ja) * | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| JP2024519628A (ja) * | 2021-05-26 | 2024-05-21 | イノキュア セラピューティクス インコーポレイテッド | ピペリジンジオン誘導体 |
| KR102474999B1 (ko) * | 2021-05-26 | 2022-12-07 | 주식회사 이노큐어테라퓨틱스 | 피페리딘디온 유도체 |
| TW202321219A (zh) | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | 雜環衍生物及其組合物和藥學上的應用 |
| WO2024054953A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2024054952A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| EP4624472A1 (en) * | 2022-11-22 | 2025-10-01 | Innocure Therapeutics, Inc. | Degrader including novel c-met protein ligand and pharmaceutical composition including same |
| KR20240076746A (ko) * | 2022-11-22 | 2024-05-30 | 주식회사 이노큐어테라퓨틱스 | Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물 |
| KR20240075764A (ko) * | 2022-11-22 | 2024-05-29 | 주식회사 이노큐어테라퓨틱스 | cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물 |
| CN116655591B (zh) * | 2023-06-05 | 2024-11-08 | 中国人民解放军军事科学院军事医学研究院 | 3,4-二氢酞嗪-1（2h）-酮类衍生物及制备方法和用途 |
| CN121773112A (zh) | 2023-08-17 | 2026-03-31 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| WO2025062330A1 (en) | 2023-09-20 | 2025-03-27 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| CN120025333A (zh) * | 2023-11-22 | 2025-05-23 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025193849A1 (en) | 2024-03-13 | 2025-09-18 | Genentech, Inc. | Polymorphs of ar-degraders |
| WO2025193851A1 (en) | 2024-03-13 | 2025-09-18 | Genentech, Inc. | Process for making enantiomers of ar-degraders |
| WO2025226797A1 (en) | 2024-04-24 | 2025-10-30 | Genentech, Inc. | Kred catalyzed ketoreduction of a cyclobutanone carbamic ester |
| US12169941B1 (en) | 2024-06-13 | 2024-12-17 | Rapsodo Pte. Ltd. | System and method for determining a position an object crosses a target plane |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| CA3042297A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110194762B (zh) * | 2018-02-27 | 2021-09-10 | 中国科学院上海药物研究所 | 酞嗪酮类衍生物、其制备方法和用途 |
| CN112390852B (zh) | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| CN112457367B (zh) | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN112457366B (zh) | 2019-09-06 | 2024-03-19 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和应用 |
| CN118930604A (zh) | 2019-09-29 | 2024-11-12 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用 |
| CN114829342A (zh) | 2019-12-23 | 2022-07-29 | 上海济煜医药科技有限公司 | 一种蛋白降解剂化合物的制备方法和应用 |
| CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| CR20230007A (es) * | 2020-06-12 | 2023-06-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y método de preparación y uso médico de este. |
-
2021
- 2021-06-11 CR CR20230007A patent/CR20230007A/es unknown
- 2021-06-11 IL IL298962A patent/IL298962A/en unknown
- 2021-06-11 PE PE2022002889A patent/PE20230610A1/es unknown
- 2021-06-11 JP JP2022576009A patent/JP7797421B2/ja active Active
- 2021-06-11 MX MX2022015562A patent/MX2022015562A/es unknown
- 2021-06-11 CN CN202110653817.9A patent/CN113801098B/zh active Active
- 2021-06-11 WO PCT/CN2021/099654 patent/WO2021249534A1/zh not_active Ceased
- 2021-06-11 AU AU2021286738A patent/AU2021286738A1/en active Pending
- 2021-06-11 CA CA3186981A patent/CA3186981A1/en active Pending
- 2021-06-11 EP EP21822688.4A patent/EP4166550A4/en active Pending
- 2021-06-11 PH PH1/2023/550018A patent/PH12023550018A1/en unknown
- 2021-06-11 CN CN202310167758.3A patent/CN116082311B/zh active Active
- 2021-06-11 KR KR1020237000214A patent/KR20230024328A/ko active Pending
- 2021-06-11 BR BR112022025057A patent/BR112022025057A2/pt unknown
- 2021-06-11 TW TW110121476A patent/TWI781651B/zh active
-
2022
- 2022-12-07 CO CONC2022/0017802A patent/CO2022017802A2/es unknown
- 2022-12-07 CL CL2022003472A patent/CL2022003472A1/es unknown
- 2022-12-12 SA SA522441725A patent/SA522441725B1/ar unknown
- 2022-12-12 US US18/079,778 patent/US20230131252A1/en active Pending
-
2023
- 2023-04-05 US US18/131,309 patent/US11767312B2/en active Active
-
2024
- 2024-08-14 US US18/804,443 patent/US12234223B2/en active Active
-
2025
- 2025-12-23 JP JP2025277389A patent/JP2026053536A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023531390A (ja) | 2023-07-24 |
| CO2022017802A2 (es) | 2023-03-17 |
| US20230242510A1 (en) | 2023-08-03 |
| CN116082311A (zh) | 2023-05-09 |
| CN113801098B (zh) | 2023-05-30 |
| IL298962A (en) | 2023-02-01 |
| PE20230610A1 (es) | 2023-04-13 |
| CR20230007A (es) | 2023-06-01 |
| US12234223B2 (en) | 2025-02-25 |
| US20240400540A1 (en) | 2024-12-05 |
| WO2021249534A1 (zh) | 2021-12-16 |
| AU2021286738A1 (en) | 2023-01-19 |
| EP4166550A4 (en) | 2024-08-07 |
| CL2022003472A1 (es) | 2023-06-02 |
| TW202146400A (zh) | 2021-12-16 |
| EP4166550A1 (en) | 2023-04-19 |
| CN116082311B (zh) | 2025-04-25 |
| PH12023550018A1 (en) | 2024-03-11 |
| KR20230024328A (ko) | 2023-02-20 |
| MX2022015562A (es) | 2023-01-30 |
| US11767312B2 (en) | 2023-09-26 |
| CN113801098A (zh) | 2021-12-17 |
| TWI781651B (zh) | 2022-10-21 |
| BR112022025057A2 (pt) | 2023-01-31 |
| CA3186981A1 (en) | 2021-12-16 |
| JP7797421B2 (ja) | 2026-01-13 |
| JP2026053536A (ja) | 2026-03-25 |
| US20230131252A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522441725B1 (ar) | مركب فثالازينون وطريقة تحضيره واستخدامه الطبي | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| NZ766978A (en) | Atr inhibitor and application thereof | |
| PH12022551571A1 (en) | Protein degradation agent compound preparation method and application | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| CR20210032A (es) | Compuestos | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| JOP20190174A1 (ar) | مثبطات jak1 انتقائية | |
| TN2018000319A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX2022006653A (es) | Compuestos para modular la actividad de fxr y usos de los mismos. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX379576B (es) | Derivados de azetidina | |
| MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
| MX2021009717A (es) | Sulfonamidas biciclicas. | |
| MX2025004545A (es) | 3,4 a, 5, 7, 8, 8a-hexahidro-4h-tiopirano [4,3-d] pirimidin-4-onas 2-sustituidas para el tratamiento de heridas | |
| BR112022008647A2 (pt) | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo | |
| MX2021014629A (es) | Compuestos tetraciclicos como inhibidores de cdc7. | |
| NZ764463A (en) | Heterocyclic compound and application thereof in medicine | |
| PH12021551437A1 (en) | Estrogen receptor antagonist | |
| EA201991932A1 (ru) | Производное азитидина |